CL2018003639A1 - Composicion solida que comprende nanoparticulas de atovacuona; proceso para prepararla; composicion farmaceutica o veterinaria; formulacion inyectable intramuscular o subcutanea; dispersiones acuosa u oleosa; procedimiento para prepararlas; metodo para tratar infecciones parasitarias y fungicas; metodo para prevenir malaria; kit. - Google Patents

Composicion solida que comprende nanoparticulas de atovacuona; proceso para prepararla; composicion farmaceutica o veterinaria; formulacion inyectable intramuscular o subcutanea; dispersiones acuosa u oleosa; procedimiento para prepararlas; metodo para tratar infecciones parasitarias y fungicas; metodo para prevenir malaria; kit.

Info

Publication number
CL2018003639A1
CL2018003639A1 CL2018003639A CL2018003639A CL2018003639A1 CL 2018003639 A1 CL2018003639 A1 CL 2018003639A1 CL 2018003639 A CL2018003639 A CL 2018003639A CL 2018003639 A CL2018003639 A CL 2018003639A CL 2018003639 A1 CL2018003639 A1 CL 2018003639A1
Authority
CL
Chile
Prior art keywords
atovaquone
prepare
aqueous
nanoparticles
composition
Prior art date
Application number
CL2018003639A
Other languages
English (en)
Inventor
Steven Paul Rannard
Andrew Owen
Alison Savage
Lee Tatham
Theresa Shapiro
Rahul P Bakshi
Godfree Mlambo
Abhai Tripathi
Original Assignee
Univ Liverpool
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Liverpool, Univ Johns Hopkins filed Critical Univ Liverpool
Publication of CL2018003639A1 publication Critical patent/CL2018003639A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una composición sólida que comprende nanopartículas de atovacuona dispersas dentro de uno o más materiales portadores, en la que la atovacuona está presente en una cantidad de al menos el 10% en peso. Un proceso para prepararla esta composición sólida. Una composición farmacéutica o veterinaria en forma inyectable por vía intramuscular y/o subcutánea. Una formulación inyectable por vía intramuscular o subcutánea de nanopartículas de atovacuona. Una dispersión acuosa u oleosa. Un procedimiento para preparar una dispersión acuosa u oleosa. Una composición sólida, una composición inyectable farmacéutica o veterinaria, una dispersión acuosa y una dispersión oleosa, para uso como monoterapia o en terapia combinada con uno o más medicamentos seleccionados de proguanil, mefloquina, cloroquina, hidroxicloroquina, quinina, quinidina, artemeter, lumefantrina, primaquina, doxiciclina, tetraciclina, clindamicina, dihidroartemisina, piperaquina, y pirimetamina con o sin sulfadoxina, en el tratamiento y/o prevención de infecciones parasitarias causadas por parásitos del género Plasmodium, Toxoplasma, o Babesiidae, tales como malaria, toxoplasmosis o bebesiosis o fúngicas causadas por el hongo del género Pneumocystis, tales como la neumonía por Phneumocystis. Un método para el tratamiento y/o prevención de una infección parasitaria o fúngica. Un método para prevenir la malaria. Un kit para la preparación de una formulación líquida estéril de nanopartículas de atovacuona para inyección.
CL2018003639A 2016-06-16 2018-12-14 Composicion solida que comprende nanoparticulas de atovacuona; proceso para prepararla; composicion farmaceutica o veterinaria; formulacion inyectable intramuscular o subcutanea; dispersiones acuosa u oleosa; procedimiento para prepararlas; metodo para tratar infecciones parasitarias y fungicas; metodo para prevenir malaria; kit. CL2018003639A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662351048P 2016-06-16 2016-06-16

Publications (1)

Publication Number Publication Date
CL2018003639A1 true CL2018003639A1 (es) 2019-08-09

Family

ID=59295233

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018003639A CL2018003639A1 (es) 2016-06-16 2018-12-14 Composicion solida que comprende nanoparticulas de atovacuona; proceso para prepararla; composicion farmaceutica o veterinaria; formulacion inyectable intramuscular o subcutanea; dispersiones acuosa u oleosa; procedimiento para prepararlas; metodo para tratar infecciones parasitarias y fungicas; metodo para prevenir malaria; kit.

Country Status (9)

Country Link
US (2) US20190321310A1 (es)
EP (1) EP3471697A1 (es)
JP (1) JP2019518057A (es)
CN (1) CN109640948B (es)
AU (1) AU2017286626B2 (es)
BR (1) BR112018076184A2 (es)
CA (1) CA3027817C (es)
CL (1) CL2018003639A1 (es)
WO (1) WO2017216564A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020081997A1 (en) * 2018-10-18 2020-04-23 Tulex Pharmaceuticals Inc. Atovaquone nanoparticulate compositions
CN115192557B (zh) * 2021-04-13 2023-12-12 储蕾 用于治疗肥大细胞介导的炎性疾病的药物组合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9226905D0 (en) * 1992-12-24 1993-02-17 Wellcome Found Pharmaceutical preparation
WO1996013254A1 (en) * 1994-10-26 1996-05-09 Glaxo Wellcome House Pharmaceutical composition comprising atovaquone
DE10036871A1 (de) * 2000-07-28 2002-02-14 Pharmasol Gmbh Dispersionen zur Formulierung wenig oder schwer löslicher Wirkstoffe
GB2399084B (en) 2002-07-30 2007-01-31 Univ Liverpool Porous beads and method of production thereof
GB0520068D0 (en) * 2005-10-03 2005-11-09 Cancer Res Technology av peptide ligand
GB0613925D0 (en) 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
CN102105427A (zh) * 2008-07-25 2011-06-22 阿尔法制药有限公司 粒度直径范围(D90)为大于3μm至约10μm的阿托伐醌
US20100028425A1 (en) * 2008-07-31 2010-02-04 Glenmark Generics Ltd. Pharmaceutical composition of atovaquone
JP6267218B2 (ja) * 2012-11-06 2018-01-24 ロチャル インダストリーズ，エルエルシー 揮発性、疎水性溶媒を用いた生物学的に活性な薬剤の送達
EP3131566B1 (en) * 2014-04-15 2022-10-05 The Regents of the University of California Bi-terminal pegylated integrin-binding peptides and methods of use thereof

Also Published As

Publication number Publication date
EP3471697A1 (en) 2019-04-24
CA3027817A1 (en) 2017-12-21
BR112018076184A2 (pt) 2019-03-26
AU2017286626A1 (en) 2019-01-24
AU2017286626B2 (en) 2023-02-02
WO2017216564A1 (en) 2017-12-21
CA3027817C (en) 2023-12-19
US20190321310A1 (en) 2019-10-24
CN109640948B (zh) 2023-05-02
CN109640948A (zh) 2019-04-16
US20230218547A1 (en) 2023-07-13
JP2019518057A (ja) 2019-06-27

Similar Documents

Publication Publication Date Title
CL2017003457A1 (es) Metodos para tratar tumores solidos usando terapia de combinacion del inhibidor de nanoparticulas mtor.
CL2018003639A1 (es) Composicion solida que comprende nanoparticulas de atovacuona; proceso para prepararla; composicion farmaceutica o veterinaria; formulacion inyectable intramuscular o subcutanea; dispersiones acuosa u oleosa; procedimiento para prepararlas; metodo para tratar infecciones parasitarias y fungicas; metodo para prevenir malaria; kit.
CO2020000328A2 (es) Formulaciones a largo plazo
CL2017003458A1 (es) Metodos para tratar malignidad hematoligica usando terapia de combinacion del inhibidor de nanoparticulas mtor.
ECSP22018209A (es) Nanopart?culas lip?dicas mejoradas para el suministro de ?cidos nucleicos
UY30431A1 (es) Suspensiones acuosas de tmc278
CO2022008697A2 (es) Compuestos moduladores de la diacilglicerol quinasa
CO2020016559A2 (es) Anticuerpos que se dirigen al gp120 de vih y métodos de uso
CL2018002549A1 (es) Eliminación del virus de la hepatitis b con agentes antivirales
CL2016002308A1 (es) Nanopartículas que comprenden un ácido hidrofóbico, un copolímero de dibloque pla-peg o plga-peg, y 1 -4- 4-dimetilamino piperidin-1-il carbonilfenil-3-4-4,6-dimorfolin-4-il-1,3,5-triazin-2-ilfenilurea composición farmacética proceso de preparación y uso para tratar cáncer
CO2018003542A2 (es) Anticuerpo anti-garp
UY37252A (es) Compuestos para el tratamiento de infección por virus de la hepatitis b
CL2016002794A1 (es) Vacuna de péptido que comprende un péptido ras mutante y un agente quimioterapéutico
CO2018003424A2 (es) Composición farmacéutica y formulación de inyección subcutánea que comprende micelas y curcuminoides para reducir la grasa localizada y método para preparar la misma”
CL2009000902A1 (es) Composicion que comprende posaconazol disuelto o disperso molecularmente en un polimero derivado de hidroxipropilcelulosa; formulacion farmaceutica que comprende a la composion; un proceso para preparar a la composicion mediante fusioextrusion; y su uso para tratar una infeccion micotica.
CU20150018A7 (es) Composición para el tratamiento de la infección por hepatitis b o coinfección por hepatitis b/hepatitis d
CO2023001340A2 (es) Formulaciones a largo plazo
BR112017004153A2 (pt) métodos para tratamento de infecções por protozoários
CO2019011546A2 (es) Compuestos y métodos para el tratamiento de enfermedades parasitarias
AR094707A1 (es) Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2
CO2020006257A2 (es) Composiciones farmacéuticas inyectables de isoxazolina y usos de las mismas contra infestación parasitaria
CL2020001548A1 (es) Tratamientos de combinación que comprenden la administración de 1h-pirazolo[4,3-b]piridinas.
BR112017001093A2 (pt) formulação aquosa compreendendo paracetamol e ibuprofeno
AR099960A1 (es) Procedimientos y composición farmaceutica para inducir una respuesta inmunitaria
CL2017001595A1 (es) Composiciones de vacuna para el virus del dengue y métodos de uso de las mismas